Grand Pharmaceutical Group Limited

SEHK:512 Stock Report

Market Cap: HK$16.8b

Grand Pharmaceutical Group Past Earnings Performance

Past criteria checks 2/6

Grand Pharmaceutical Group has been growing earnings at an average annual rate of 12.9%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 12.8% per year. Grand Pharmaceutical Group's return on equity is 15.3%, and it has net margins of 22.7%.

Key information

12.9%

Earnings growth rate

11.5%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate12.8%
Return on equity15.3%
Net Margin22.7%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 19
Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Jun 05
Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

May 22
Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Apr 25
Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Mar 25
Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Oct 20
We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Sep 26
Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Jun 04
Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?

May 05
Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Nov 21
Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?

Sep 05
Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Aug 16
Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Jul 28
Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11

May 29
Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?

Apr 08
Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?

Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet

Mar 22
Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet

If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late

Jan 24
If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late

These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Dec 13
These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price

Nov 27
Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price

With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting

Oct 25
With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting

China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly

Sep 01
China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly

Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?

Jul 12
Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?

Revenue & Expenses Breakdown

How Grand Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SEHK:512 Revenue, expenses and earnings (HKD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2410,5872,4093,7440
31 Mar 2410,5582,1443,8020
31 Dec 2310,5301,8803,8600
30 Sep 2310,4342,1393,8220
30 Jun 2310,3392,3983,7830
31 Mar 239,9512,2393,5790
31 Dec 229,5622,0793,3740
30 Sep 229,4031,9953,3860
30 Jun 229,2441,9103,3990
31 Mar 228,9212,1563,3590
31 Dec 218,5982,4033,3190
30 Sep 218,1312,3403,2230
30 Jun 217,6642,2773,1260
31 Mar 217,0082,0352,8360
31 Dec 206,3531,7932,5450
30 Sep 206,3061,5582,5340
30 Jun 206,2591,3232,5230
31 Mar 206,4251,2372,6860
31 Dec 196,5911,1512,8490
30 Sep 196,4501,0482,6880
30 Jun 196,3099442,5260
31 Mar 196,1348282,4190
31 Dec 185,9587132,3120
30 Sep 185,8456422,3640
30 Jun 185,7325702,4150
31 Mar 185,2515162,1410
31 Dec 174,7714611,8670
30 Sep 174,4804131,7280
30 Jun 174,1903641,5900
31 Mar 173,9433171,4570
31 Dec 163,6962691,3240
30 Sep 163,5732411,2450
30 Jun 163,4502131,1670
31 Mar 163,3481971,1190
31 Dec 153,2461811,0710
30 Sep 153,1581871,0210
30 Jun 153,0711949710
31 Mar 153,0971859760
31 Dec 143,1221759810
30 Sep 143,0401509320
30 Jun 142,9581268840
31 Mar 142,8081138280

Quality Earnings: 512 has high quality earnings.

Growing Profit Margin: 512's current net profit margins (22.7%) are lower than last year (23.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 512's earnings have grown by 12.9% per year over the past 5 years.

Accelerating Growth: 512's earnings growth over the past year (0.4%) is below its 5-year average (12.9% per year).

Earnings vs Industry: 512 earnings growth over the past year (0.4%) did not outperform the Pharmaceuticals industry 9.4%.

Return on Equity

High ROE: 512's Return on Equity (15.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 12:11
End of Day Share Price 2024/12/31 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Grand Pharmaceutical Group Limited is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yanyin ZhuChina International Capital Corporation Limited
Xiao Wei LinEverbright Securities Co. Ltd.
Yiling ChenGuosen Securities Co., Ltd.